View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, Oct. 9 (HealthDay News) -- Leptin, a molecule typically associated with obesity, has been shown to be overproduced in thyroid cancers and is associated with more aggressive disease and poorer prognosis, according to a Middle Eastern study presented at the American Association for Cancer Research Frontiers in Basic Cancer Research Meeting, held from Oct. 8 to 11 in Boston.
Khawla S. Al-Kuraya, M.D., of King Faisal Specialist Hospital and Research Center in Riyadh, Saudi Arabia, and colleagues evaluated leptin levels as well as the association between the expression of the leptin receptor (Ob-R) in 536 human thyroid cancer samples and tumor characteristics.
The researchers found that 80 percent of cancers overexpressed the Ob-R, which was significantly associated with poor disease-free survival, older age, larger tumor size, advanced staged disease, and metastasis. Further in vitro studies using thyroid cancer cells that overexpressed the Ob-R showed that leptin stimulated cell growth and inhibited cell death via the PI3K/AKT signaling pathway and further downstream signaling molecules.
"Altogether these data suggest that leptin plays a critical role in PTC [papillary thyroid cancer] pathogenesis through PI3K/AKT pathway via Ob-R and is a potential prognostic marker associated with an aggressive phenotype and poor disease free survival," the researchers conclude.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top